Breast cancer is the second leading cause of cancer death in women worldwide, second only to lung cancer. If we put it into a simple statistic, 1 in 39 women will die from this condition.
This type of cancer usually occurs at early ages due to some genetic mutations. The main ones are in the BRCA1 and BRCA2 genes.
Genes BRCA1 (BReast CAncer 1) y BRCA2 (BReast CAncer 2) are considered tumor suppressor genes. They are responsible for the production of proteins of great importance in the DNA repair. When there is any failure o mutation in any of these genes, As a result, the natural repair process is altered and general mutations accumulate throughout our DNA. This causes the cells do not behave as they should, and eventually triggers what we know as the cancer cells. Mutations in these genes have also been shown to promote the development of ovarian cancer and prostate cancer in men. At the present time there are therapies that function better depending on whether certain mutations exist in these genes or not. This makes our forecast improve significantly, in the case of already suffering from a tumor.
At GENOLIFE we recommend the sequencing study of the BRCA1 and BRCA2 genes, especially in cases where several family members have already had breast or ovarian cancer. Knowing in time can help us to prevent and take measures.
The BRCA1 and BRCA2 gene sequencing test is very simple. The sample is either a buccal swab (taken with a swab—a completely painless procedure) or a blood sample. It depends on each person’s preference, as both methods are equally reliable. Due to the nature of the test, results are typically available within 45 business days.
BRCA1 and BRCA2 sequencing
- Digital and in-app reporting
Benefits of a genetic study for cancer.
Thanks to the genetic study for cancer we can have reliable information to make a decision that will help us to establish a personalized treatment and fight more effectively against this disease.